Publications
219
Citations
2,311
Est. group size
~53
Recurring co-author estimate
Active years
18
Publishing since 2008
Hannah Choe's research focuses on bone marrow and stem cell transplantation, particularly the diagnosis, prediction, and treatment of graft-versus-host disease (GVHD), a common complication where transplanted donor immune cells attack the recipient's body. Her work includes clinical trials of new drugs for both acute and chronic GVHD, as well as studies developing biomarker-based tools to predict how patients will respond to treatment. This research is aimed at improving outcomes for patients undergoing hematopoietic (blood) stem cell transplants for blood cancers and other conditions.
Publication output has grown substantially over the last decade, rising from single digits in 2017 to over 40 publications in 2024-2025, indicating an active and expanding research program.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Blood Advances · 2025
- The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
Blood Advances · 2025
- RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT
Blood · 2025
- Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC
Blood Advances · 2025
- Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
Transplantation and Cellular Therapy · 2025
- Current therapeutics for sclerotic and fibrotic manifestations of chronic graft-versus-host disease
Bone Marrow Transplantation · 2025
- The Phase 2 Stargaze Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort
Transplantation and Cellular Therapy · 2025
- Kinetics and Management of Hepatic Laboratory Elevations Associated with Axatilimab in the Agave-201 Study
Transplantation and Cellular Therapy · 2025
- Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program
Blood · 2025
- Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies
Blood · 2025
- 204. <i>Clostridioides difficile</i> screening among asymptomatic carriers admitted for bone marrow transplantation: Navigating optimal stewardship strategies
Open Forum Infectious Diseases · 2025
- Clinical Outcomes of Treatment-Refractory Sclerodermatous Chronic Gvhd Patients Treated with IL-4/IL-13 Inhibition
Transplantation and Cellular Therapy · 2025
- Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Bone Marrow Transplantation · 2025
- Interprofessional Management of Dental Extractions in a Severely Neutropenic Patient Prior to Bone Marrow Transplantation
2025
- Grade I acute graft-vs-host disease: Treat or not?
Blood · 2025
- Blood×66
- Transplantation and Cellular Therapy×49
- Blood Advances×19
- Biology of Blood and Marrow Transplantation×18
- Bone Marrow Transplantation×9
- Julianna Roddy
Medicine · The Ohio State University
- Marcos de Lima
Medicine · The Ohio State University
- Ayman Saad
Medicine · The Ohio State University
- Jennifer E. Schwartz
Medicine · Indiana University
- Patrick Elder
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile